Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Di Perri

Showing results (61-70 of 177) with videos related to

Pageof 18
Sort By:
The Journal of Antimicrobial Chemotherapy|June 6, 2006
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three casesS Garazzino, M Tettoni, A Calcagno, et al.
HIV Medicine|May 18, 2019
Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamideS D Shafran, G Di Perri, S Esser, et al.
Giornale Italiano Di Chemioterapia|May 1, 1986
[Opportunistic mycotic infections in AIDS. Brief review and presentation of 2 clinical cases]G Michelone, G Senaldi, G Di Perri, et al.
AIDS (London, England)|April 1, 1989
Usefulness of computerized electroencephalography in diagnosing, staging and monitoring AIDS-dementia complexA Parisi, G Di Perri, M Strosselli, et al.
Giornale Italiano Di Chemioterapia|January 1, 1986
[Trials and prospectives in the treatment of AIDS]G Senaldi, G Di Perri, G Michelone, et al.
Le Infezioni in Medicina|June 28, 2002
A case of flare syndromeA Maiello, D Racca, D A Zeme, et al.
American Journal of Respiratory and Critical Care Medicine|August 1, 1994
Manifestations of TB to CD4 cell countsG Di Perri, S Vento, A Cazzadori, et al.
Drugs Under Experimental and Clinical Research|January 1, 1990
In vitro antibacterial activity of cefotaxime and desacetylcefotaxime, alone or in combination, against gram-positive cocciM Cruciani, A Navarra, G Di Perri, et al.
Journal of Viral Hepatitis|July 26, 2014
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferonL Boglione, J Cusato, A De Nicolò, et al.
Journal of Viral Hepatitis|March 7, 2014
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevirL Boglione, A De Nicolò, J Cusato, et al.
Pageof 18

Showing results (61-70 of 177) with videos related to

Sort By:
Pageof 18
The Journal of Antimicrobial Chemotherapy|June 6, 2006
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three casesS Garazzino, M Tettoni, A Calcagno, et al.
HIV Medicine|May 18, 2019
Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamideS D Shafran, G Di Perri, S Esser, et al.
Giornale Italiano Di Chemioterapia|May 1, 1986
[Opportunistic mycotic infections in AIDS. Brief review and presentation of 2 clinical cases]G Michelone, G Senaldi, G Di Perri, et al.
AIDS (London, England)|April 1, 1989
Usefulness of computerized electroencephalography in diagnosing, staging and monitoring AIDS-dementia complexA Parisi, G Di Perri, M Strosselli, et al.
Giornale Italiano Di Chemioterapia|January 1, 1986
[Trials and prospectives in the treatment of AIDS]G Senaldi, G Di Perri, G Michelone, et al.
Le Infezioni in Medicina|June 28, 2002
A case of flare syndromeA Maiello, D Racca, D A Zeme, et al.
American Journal of Respiratory and Critical Care Medicine|August 1, 1994
Manifestations of TB to CD4 cell countsG Di Perri, S Vento, A Cazzadori, et al.
Drugs Under Experimental and Clinical Research|January 1, 1990
In vitro antibacterial activity of cefotaxime and desacetylcefotaxime, alone or in combination, against gram-positive cocciM Cruciani, A Navarra, G Di Perri, et al.
Journal of Viral Hepatitis|July 26, 2014
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferonL Boglione, J Cusato, A De Nicolò, et al.
Journal of Viral Hepatitis|March 7, 2014
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevirL Boglione, A De Nicolò, J Cusato, et al.
Pageof 18